TABLE 3.
Current clinical trials/status of PLGA-based micro/nanoparticles therapy and diagnostics.
| Name | Carrier | Drug | Investigated applications | Company | Status | Ref |
|---|---|---|---|---|---|---|
| Pamorelin® | PLGA microsphere | Triptorelin | Prostate cancer | Ipsen Pharmaceuticals | Approved 1986 | Jain et al. (2016) |
| Lupron Depot® | PLGA microsphere | Leuprolide acetate | Prostate cancer, Endometriosis | Takeda-Abbott Products | Approved 1989 | Anselmo and itragotri, (2014) |
| Central precocious puberty | ||||||
| Sandostatin Lar® | PLGA microsphere | Octreotide acetate | Endocrinology and Metabolism; Acromegaly | Novartis pharmaceuticals corp | Approved 1998 | Zhong et al. (2018) |
| Trelstar® | PLGA microsphere | Triptorelin pamoate | Prostate cancer | Allergen DM | Approved 2000 | Nkanga et al. (2020) |
| Arestin® | PLGA microsphere | Minocycline HCl | Infectious Diseases | Orapharma Inc. | Approved 2001 | Molavi et al. (2020) |
| Periodontitis | ||||||
| Eligard® | PLGA depot | Leuprolide acetate | Prostate cancer | Atrix Laboratories (Tolmar Therapeutics) | Approved 2002 | Bobo et al. (2016) |
| Risperdal Consta® | PLGA microsphere | Risperidone | Neurologic Disorders antipsychotic | Janssen Pharmaceuticals Inc. | Approved 2003 | Hrkach and Langer, (2020) |
| Vivitrol® | PLGA microsphere | Naltrexone | alcohol dependence | Alkermes Inc. | Approved 2006/2010 | Dean (2005) |
| opioid dependence | ||||||
| Ozurdex® | PLGA microsphere | Dexamethasone | Corticosteroid | Allergan Inc. | Approved 2009 | Cao et al. (2019) |
| Bydureon® | PLGA microsphere | Exenatide | Type II diabetes | Amylin Pharmaceuticals | Approved 2012 | Fineman et al. (2011) |
| Bydureon Bcise® | PLGA microsphere | Exenatide | Type II diabetes | AstraZeneca AB | Approved 2017 | Rentzepis et al. (2018) |
| Signifor Lar® | PLGA microsphere | Pasireotide pamoate | Acromegaly | Novartis | Approved 2014 | McKeage, (2015) |
| Zilretta® | PLGA microsphere | Triamcinolone | Osteoarthritis | Flexion Therapeutics Inc. | Approved 2017 | Chen et al. (2021) |
| Other corticosteroid therapy | ||||||
| Triptodur® | PLGA microsphere | Triptorelin pamoate | Central precocious puberty | Arbor | Approved 2017 | Ghitman et al., 2020 |
| Sublocade® | PLGA nanoparticles | Buprenorphine | Moderate to severe addiction to opioid drugs | Indivior Pharmaceuticals | Approved 2017 | Chaurasiya et al. (2021) |